FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999696783> ?p ?o ?g. }

• W2999696783 abstract "Abstract Background We aimed to evaluate the effectiveness of tumour necrosis factor antagonist (anti-TNF) compared with vedolizumab (VDZ) as a second-line biological treatment in IBD. Methods A propensity score-matched cohort was created using data from the Swedish National Patient Register, the Swedish Quality Register for IBD (SWIBREG) and the Swedish Prescribed Drug Register. Patients with Crohn’s disease (CD) or ulcerative colitis (UC) exposed to anti-TNF as a first-line biologic, who initiated a second biologic agent 1 May 2014 – 31 December 2016 were included (n = 1363). We compared patients exposed to anti-TNF vs. patients exposed to VDZ as a second-line biologic treatment. The primary outcome was drug continuation rate at 12 months. Secondarily, we assessed survival without hospitalisation (because of IBD, complications of IBD or IBD-related surgery) and survival without IBD-related surgery. Risk of infections was investigated as survival without a) prescription of antibiotics and b) hospitalisation because of infection. Additionally, the proportion of patients on corticosteroids at 12 months was assessed. Results After 1:1 propensity score matching, the cohort was restricted to 400 patients (CD, n = 198; UC, n = 202). For CD, estimated drug continuation rate at 12 months was 72.7% in the VDZ-treated patients, compared with 73.7% in the anti-TNF treated patients (Figure 1A). Survival without IBD-related hospitalisation (81.8% vs. 87.9%, p = 0.25), IBD-related surgery (81.8% vs. 88.9%, p = 0.17), prescription of antibiotics (64.6% vs. 70.7%, p = 0.33) and hospitalisation due to infection (94.9 % vs. 87.9%, p = 0.08) did not significantly differ between the groups. Likewise, there was no statistically significant difference in proportions of patients on corticosteroids at 12 months (21.2% vs. 22.2%, p = 0.86). For UC, estimated drug continuation rate at 12 months was 69.3% in the VDZ-treated patients, compared with 62.4% in the anti-TNF treated patients (Figure 1B). VDZ treated patients had lower survival without IBD-related hospitalisation (82.2% vs. 93.1%, p = 0.02) and IBD-related surgery (82.2% vs. 94.1%, p = 0.01). Survival without antibiotics (81.2% vs. 70.3%, p = 0.08) and hospitalisation due to infection (92.1% vs. 92.1%, p = 0.97) as well as corticosteroid treatment at 12 months (17.8% vs. 23.8%, p = 0.30) did not differ significantly between the groups. Conclusion In this propensity score-matched cohort, the effectiveness and safety of anti-TNF and vedolizumab appear comparable when used as a second-line biologic in CD. In patients with UC, risk of hospitalisation and surgery was lower in patients treated with anti-TNF. Randomised controlled trials are needed to confirm these findings. Support provided by Takeda." @default.
• W2999696783 created "2020-01-23" @default.
• W2999696783 creator A5000300261 @default.
• W2999696783 creator A5003455196 @default.
• W2999696783 creator A5019960092 @default.
• W2999696783 creator A5025037358 @default.
• W2999696783 creator A5068091489 @default.
• W2999696783 creator A5087768306 @default.
• W2999696783 date "2020-01-01" @default.
• W2999696783 modified "2023-10-02" @default.
• W2999696783 title "P327 Effectiveness of anti-TNF vs. vedolizumab as a second biologic in IBD: results from national Swedish registers" @default.
• W2999696783 doi "https://doi.org/10.1093/ecco-jcc/jjz203.456" @default.
• W2999696783 hasPublicationYear "2020" @default.
• W2999696783 type Work @default.
• W2999696783 sameAs 2999696783 @default.
• W2999696783 citedByCount "0" @default.
• W2999696783 crossrefType "journal-article" @default.
• W2999696783 hasAuthorship W2999696783A5000300261 @default.
• W2999696783 hasAuthorship W2999696783A5003455196 @default.
• W2999696783 hasAuthorship W2999696783A5019960092 @default.
• W2999696783 hasAuthorship W2999696783A5025037358 @default.
• W2999696783 hasAuthorship W2999696783A5068091489 @default.
• W2999696783 hasAuthorship W2999696783A5087768306 @default.
• W2999696783 hasBestOaLocation W29996967831 @default.
• W2999696783 hasConcept C126322002 @default.
• W2999696783 hasConcept C141071460 @default.
• W2999696783 hasConcept C17923572 @default.
• W2999696783 hasConcept C17991360 @default.
• W2999696783 hasConcept C201903717 @default.
• W2999696783 hasConcept C2426938 @default.
• W2999696783 hasConcept C2776207728 @default.
• W2999696783 hasConcept C2777138892 @default.
• W2999696783 hasConcept C2778260677 @default.
• W2999696783 hasConcept C2779134260 @default.
• W2999696783 hasConcept C2779280984 @default.
• W2999696783 hasConcept C2780479503 @default.
• W2999696783 hasConcept C501593827 @default.
• W2999696783 hasConcept C71924100 @default.
• W2999696783 hasConcept C72563966 @default.
• W2999696783 hasConcept C86803240 @default.
• W2999696783 hasConcept C89423630 @default.
• W2999696783 hasConcept C90924648 @default.
• W2999696783 hasConcept C98274493 @default.
• W2999696783 hasConceptScore W2999696783C126322002 @default.
• W2999696783 hasConceptScore W2999696783C141071460 @default.
• W2999696783 hasConceptScore W2999696783C17923572 @default.
• W2999696783 hasConceptScore W2999696783C17991360 @default.
• W2999696783 hasConceptScore W2999696783C201903717 @default.
• W2999696783 hasConceptScore W2999696783C2426938 @default.
• W2999696783 hasConceptScore W2999696783C2776207728 @default.
• W2999696783 hasConceptScore W2999696783C2777138892 @default.
• W2999696783 hasConceptScore W2999696783C2778260677 @default.
• W2999696783 hasConceptScore W2999696783C2779134260 @default.
• W2999696783 hasConceptScore W2999696783C2779280984 @default.
• W2999696783 hasConceptScore W2999696783C2780479503 @default.
• W2999696783 hasConceptScore W2999696783C501593827 @default.
• W2999696783 hasConceptScore W2999696783C71924100 @default.
• W2999696783 hasConceptScore W2999696783C72563966 @default.
• W2999696783 hasConceptScore W2999696783C86803240 @default.
• W2999696783 hasConceptScore W2999696783C89423630 @default.
• W2999696783 hasConceptScore W2999696783C90924648 @default.
• W2999696783 hasConceptScore W2999696783C98274493 @default.
• W2999696783 hasLocation W29996967831 @default.
• W2999696783 hasOpenAccess W2999696783 @default.
• W2999696783 hasPrimaryLocation W29996967831 @default.
• W2999696783 hasRelatedWork W12927781 @default.
• W2999696783 hasRelatedWork W13079741 @default.
• W2999696783 hasRelatedWork W14576825 @default.
• W2999696783 hasRelatedWork W16961017 @default.
• W2999696783 hasRelatedWork W18725558 @default.
• W2999696783 hasRelatedWork W2441151 @default.
• W2999696783 hasRelatedWork W4496315 @default.
• W2999696783 hasRelatedWork W518170 @default.
• W2999696783 hasRelatedWork W18229354 @default.
• W2999696783 hasRelatedWork W18754598 @default.
• W2999696783 isParatext "false" @default.
• W2999696783 isRetracted "false" @default.
• W2999696783 magId "2999696783" @default.
• W2999696783 workType "article" @default.